Serina Therapeutics’ (SER) “Buy” Rating Reiterated at BTIG Research

Serina Therapeutics (NYSEAMERICAN:SER)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $8.00 price target on the stock. BTIG Research‘s target price would suggest a potential upside of 388.70% from the company’s current price.

Serina Therapeutics Stock Down 0.8%

Shares of NYSEAMERICAN:SER traded down $0.01 during trading on Monday, hitting $1.64. 22,389 shares of the company were exchanged, compared to its average volume of 1,431,694. The firm’s 50 day moving average price is $2.24 and its 200-day moving average price is $2.08. The stock has a market capitalization of $41.58 million, a P/E ratio of -0.87 and a beta of 1.19. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.65 and a quick ratio of 6.65. Serina Therapeutics has a 12-month low of $1.22 and a 12-month high of $5.25.

Serina Therapeutics (NYSEAMERICAN:SER) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) EPS for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to provide longer-lasting and more consistent therapeutic effects. The company uses its proprietary POZ polymer technology to modify existing drug compounds, with the goal of extending their duration of action and potentially improving treatment convenience and tolerability.

Serina’s lead program is POZ-apomorphine, also referred to as SER-252, an investigational therapy being developed for patients with advanced Parkinson’s disease.